SCHEMBL2978356

SCHEMBL2978356

COc1ccc(Nc2nnc(-c3nc(NCCN4C(=O)NC(=O)C4(C)C)ncc3Cl)s2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GUSB P08236 1/20 0.39
MAPT P10636 4/20 0.39
PLK1 P53350 3/20 0.37
CCND3 P30281 2/20 0.37
EGFR P00533 1/20 0.37
FGFR1 P11362 1/20 0.37
SRC P12931 1/20 0.37
CCNK O75909 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CDK9 P50750 1/20 0.37
CDK6 Q00534 1/20 0.37
KDR P35968 2/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
HDAC1 Q13547 2/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
CDK4 P11802 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2985133 0.90 MARK3 (0.36) PLK1CCND3EGFRFGFR1SRC
SCHEMBL5147385 0.80 MAPK1 (0.35) FGFR1CCNKCDK9TP53MEN1
SCHEMBL2986223 0.79 FGFR1 (0.35) CCND3EGFRFGFR1CCNA2CDK2
SCHEMBL2983794 0.75 MEN1 (0.31) MEN1KMT2AUSP2ALDH1A1CYP1A2
SCHEMBL2980191 0.72 JAK2 (0.33) PLK1CCND3CDK2CDK9CDK6
SCHEMBL13685006 0.71 LRRK2 (0.36) CCND3CCNKCCNA2CDK2CDK9
SCHEMBL2981463 0.70 JAK2 (0.33) PLK1CCND3EGFRCDK4CCND1
SCHEMBL2988460 0.70 PDE3B (0.32) PLK1KDRTP53MEN1KMT2A
SCHEMBL2988266 0.70 PDE7A (0.43) MEN1KMT2AUSP2ALDH1A1CYP1A2
SCHEMBL2988264 0.70 PDE7A (0.43) MEN1KMT2AUSP2ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 EP claimed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 US claimed
US-20070185133-A1 Aminopyrimidine compounds and methods of use AMGEN, INC. (US) 2007-08-09 US claimed
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 EP disclosed
US-7858785-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7786132-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-08-31 US disclosed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 US disclosed
EP-1831207-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-09-12 EP disclosed
US-20070185133-A1 Aminopyrimidine compounds and methods of use AMGEN, INC. (US) 2007-08-09 US disclosed
WO-2006066172-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PLK1, TYMP, TK2 GUSB 2595/4885MAPT 1412/4885PLK1 1/4885
US-20070185133-A1 Aminopyrimidine compounds and methods of use PLK1, TYMP, TK2 GUSB 2595/4885MAPT 1412/4885PLK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.